RT Journal Article
T1 GOECP/SEOR radiotherapy guidelines for small-cell lung cancer.
A1 Couñago, Felipe
A1 de la Pinta, Carolina
A1 Gonzalo, Susana
A1 Fernández, Castalia
A1 Almendros, Piedad
A1 Calvo, Patricia
A1 Taboada, Begoña
A1 Gómez-Caamaño, Antonio
A1 Guerra, José Luis López
A1 Chust, Marisa
A1 González Ferreira, José Antonio
A1 Álvarez González, Ana
A1 Casas, Francesc
K1 Brain metastases
K1 Chemotherapy
K1 Hyperfractionated radiation therapy
K1 Prophylactic brain irradiation
K1 Reirradiation
K1 Small cell lung cancer
AB Small cell lung cancer (SCLC) accounts for approximately 20% of all lung cancers. The main treatment is chemotherapy (Ch). However, the addition of radiotherapy significantly improves overall survival (OS) in patients with non-metastatic SCLC and in those with metastatic SCLC who respond to Ch. Prophylactic cranial irradiation reduces the risk of brain metastases and improves OS in both metastatic and non-metastatic patients. The 5-year OS rate in patients with limited-stage disease (non-metastatic) is slightly higher than 30%, but less than 5% in patients with extensive-stage disease (metastatic). The present clinical guidelines were developed by Spanish radiation oncologists on behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Society of Radiation Oncology to provide a current review of the diagnosis, planning, and treatment of SCLC. These guidelines emphasise treatment fields, radiation techniques, fractionation, concomitant treatment, and the optimal timing of Ch and radiotherapy. Finally, we discuss the main indications for reirradiation in local recurrence.
SN 2218-4333
YR 2021
FD 2021
LK https://hdl.handle.net/10668/27369
UL https://hdl.handle.net/10668/27369
LA en
DS RISalud
RD Apr 18, 2025